1-Hydroxy-6-nitrobenzotriazole, also known as **6-nitrobenzotriazole**, is a heterocyclic organic compound with the molecular formula C6H3N3O3.
**Here's why it's important for research:**
* **Metal Chelator:** This compound acts as a strong chelating agent, binding to metals like copper, iron, and nickel. This property makes it useful in several applications:
* **Corrosion Inhibition:** 6-nitrobenzotriazole can be used to prevent corrosion of metals, especially in harsh environments.
* **Catalysis:** It can modify the activity of metal catalysts in various reactions.
* **Analytical Chemistry:** It can be used in analytical methods for detecting and quantifying metal ions.
* **Dye Synthesis:** The compound is a key intermediate in the synthesis of various dyes, pigments, and colorants.
* **Medicinal Chemistry:** 6-nitrobenzotriazole has shown some potential in medicinal chemistry research, particularly in the development of:
* **Antimicrobial agents:** Some derivatives have demonstrated antibacterial and antifungal properties.
* **Anti-inflammatory agents:** Research suggests potential for treating inflammation-related conditions.
* **Antioxidant agents:** It may act as an antioxidant, protecting cells from damage.
* **Other Applications:**
* **Organic Synthesis:** It serves as a building block for synthesizing a variety of other organic compounds.
* **Material Science:** It has applications in the development of new materials, particularly in the area of polymer stabilization.
**Safety Considerations:**
While 6-nitrobenzotriazole is useful in research, it's important to handle it with caution. It is considered a potential skin and eye irritant, and it should be used in well-ventilated areas.
**Overall, 1-hydroxy-6-nitrobenzotriazole is a versatile compound with applications in various research areas, particularly in metal coordination chemistry, dye synthesis, and medicinal chemistry.**
1-hydroxy-6-nitrobenzotriazole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 152817 |
| CHEMBL ID | 1346117 |
| SCHEMBL ID | 3279685 |
| MeSH ID | M0128581 |
| Synonym |
|---|
| smr000146533 |
| MLS000554216 |
| 6-nitro-benzotriazol-1-ol |
| ohnbt |
| 1-hydroxy-6-nitrobenzotriazole |
| AKOS003263811 |
| NCGC00246302-01 |
| HMS2555O16 |
| 1h-benzotriazole, 1-hydroxy-6-nitro- |
| 26185-63-7 |
| 6-nitro-1h-benzotriazol-1-ol |
| STK534846 |
| SCHEMBL3279685 |
| 1-hydroxy-6-nitro-1,2,3-benzotriazole |
| HZPVTKPGROKWRL-UHFFFAOYSA-N |
| CHEMBL1346117 |
| DTXSID20180813 |
| 6-nitrobenzotriazole n-oxide |
| 6-nitro-1h-benzo[d][1,2,3]triazol-1-ol |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 89.1251 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| geminin | Homo sapiens (human) | Potency | 0.1300 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 2.8184 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||